Document is current
Any future updates will be listed below
-
Authors
Mzoughi, Slim
Fong, Jia Yi
Papadopoli, David
Koh, Cheryl M.
Hulea, Laura http://orcid.org/0000-0001-7585-7760
Pigini, Paolo
Di Tullio, Federico http://orcid.org/0000-0001-9756-976X
Andreacchio, Giuseppe
Hoppe, Michal Marek http://orcid.org/0000-0002-0364-6080
Wollmann, Heike
Low, Diana
Caldez, Matias J.
Peng, Yanfen
Torre, Denis
Zhao, Julia N.
Uchenunu, Oro
Varano, Gabriele
Motofeanu, Corina-Mihaela
Lakshmanan, Manikandan
Teo, Shun Xie
Wun, Cheng Mun
Perini, Giovanni
Tan, Soo Yong
Ong, Chee Bing http://orcid.org/0000-0002-0521-1646
Al-Haddawi, Muthafar
Rajarethinam, Ravisankar
Hue, Susan Swee-Shan
Lim, Soon Thye
Ong, Choon Kiat http://orcid.org/0000-0001-6402-4288
Huang, Dachuan http://orcid.org/0000-0002-7518-4081
Ng, Siok-Bian
Bernstein, Emily
Hasson, Dan
Wee, Keng Boon
Kaldis, Philipp http://orcid.org/0000-0002-7247-7591
Jeyasekharan, Anand http://orcid.org/0000-0001-9816-6137
Dominguez-sola, David
Topisirovic, Ivan http://orcid.org/0000-0002-5510-9762
Guccione, Ernesto
-
Funding
Funding for this research was provided by:
Center for Strategic Scientific Initiatives, National Cancer Institute (P30 CA196521)
- License Information
-
More Information
Article History
Received: 14 March 2020
Accepted: 1 June 2020
First Online: 14 July 2020
Competing interests
: The authors declare the following competing interests: E.G. and K.B.W. have filed a patent application for the PRDM15 AON/SSO used in the manuscript. Method of treating cancer by antisense oligonucleotides targeting PRDM15. WO 2018/044239. The remaining authors declare no competing interests.
